Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeGLP-1Which GLP-1 for women

Evidence review · Drug selection

The best GLP-1 for women: what the trial evidence actually supports

Medically reviewed by Jane Novak, MD, MPH, MD, MPH · Endocrinology · Internal Medicine 13 min read Fact checked Editorial integrityUpdated Jul 18, 2026

The honest verdict

On efficacy alone, tirzepatide (Zepbound) produced the largest mean weight loss in trials for both sexes. But "best for women" is really about matching the drug to your specific situation — PCOS, perimenopause, or a pregnancy plan each change the calculus. There is no female-specific GLP-1.

The options, side-by-side

GLP-1 drug options for women with trial evidence and fit notes.
DrugTrial evidenceFit note
Tirzepatide (Zepbound)SURMOUNT-1: −20.9% mean lossHighest efficacy; best for maximum weight loss if covered/affordable
Semaglutide (Wegovy)STEP-1: −14.9% mean lossStrong efficacy + CV benefit (SELECT); widest insurance coverage
Semaglutide (Ozempic, off-label)Same molecule as WegovyOften used when Wegovy is not covered but Ozempic is (diabetes indication)
Liraglutide (Saxenda)SCALE: −8% mean lossDaily injection, older, lower efficacy — rarely first choice now

Drug selection is a prescriber decision. This table summarizes the trial evidence — it is not a prescription or a substitute for clinical judgment.

Is there a "female" GLP-1? No — and here is why that matters

There is no GLP-1 receptor agonist formulated for, or FDA-approved specifically for, women. Wegovy, Ozempic, Zepbound, and Mounjaro all work by the same mechanism — GLP-1 (and for tirzepatide, GIP) receptor agonism — regardless of sex. Marketing that implies a "women's version" is describing a program or a dose, not a distinct drug.

The pivotal trials enrolled both sexes with women in the majority. STEP-1 was ~74% female; SURMOUNT-1 was ~68% female. Pre-specified sub-group analyses in both trials showed no clinically meaningful sex difference in the primary weight-loss endpoint — women responded similarly to, or marginally better than, men.

So "best GLP-1 for women" is really "which GLP-1 best fits a woman's specific situation" — and that is where PCOS, contraception, pregnancy planning, and menopause enter the decision.

PCOS: the sub-population where the "for women" question is most real

Polycystic ovary syndrome affects an estimated 8-13% of reproductive-age women and is driven substantially by insulin resistance. GLP-1s improve insulin sensitivity, and small trials (e.g., a 2023-2024 body of PCOS-specific semaglutide and tirzepatide studies) show weight loss plus improved menstrual regularity and, in some patients, restored ovulation.

The clinically important consequence: fertility can return unexpectedly. Women with PCOS who were previously anovulatory may begin ovulating within weeks of starting a GLP-1. Because the drugs must be discontinued before pregnancy, reliable contraception is essential unless you are actively planning to conceive with your prescriber's involvement.

For PCOS specifically, either semaglutide or tirzepatide is reasonable. Tirzepatide's larger weight-loss effect may translate to greater metabolic improvement, but head-to-head PCOS trials are limited. This is a per-patient prescriber decision.

Pregnancy planning changes the drug decision

For any woman who might become pregnant, the pregnancy washout requirement is part of the "best drug" decision. FDA labels for Wegovy and Ozempic recommend discontinuing at least 2 months before a planned pregnancy; tirzepatide is discontinued before conception with a shorter half-life-based window.

If you are planning pregnancy within the year, this materially affects whether starting a GLP-1 now makes sense at all — you will need to stop before conception and can expect some weight regain during the washout. See our dedicated washout guide for the practical timeline.

Perimenopause and menopause: same drug, different support

Weight gain around menopause is driven by declining estrogen, muscle-mass loss, and shifting fat distribution (toward visceral/abdominal fat). GLP-1 efficacy is preserved through the menopause transition — the drugs work as well after menopause as before, and the visceral-fat reduction they drive is exactly the fat depot that rises after menopause.

What changes is the support strategy, not the drug. Post-menopausal women lose muscle faster during rapid weight loss, and bone mineral density is already declining — so protein intake (0.7-1.0 g per lb goal weight) and resistance training (2+ sessions/week, which loads bone) matter more in this group. The right answer is the same high-efficacy GLP-1 plus deliberate lean-mass and bone protection, not a different medication.

If you are on hormone replacement therapy (HRT), there is no known interaction with GLP-1s — the two are commonly used together. Oral estrogen absorption is theoretically affected by slowed gastric emptying, but this has not proven clinically significant; discuss timing with your prescriber if you take oral HRT.

Dosing and titration: what the schedule actually looks like

Both drugs use a mandatory slow dose-escalation to build GI tolerance. For Wegovy: 0.25 mg weekly for 4 weeks, then 0.5, 1.0, 1.7, and finally 2.4 mg (maintenance), each step held ~4 weeks — reaching maintenance around week 16-20. For Zepbound: 2.5 mg weekly for 4 weeks, then 5, 7.5, 10, 12.5, up to 15 mg, escalating no faster than every 4 weeks.

The starting doses are deliberately sub-therapeutic — they exist to let your gut adapt, not to drive weight loss. Expecting big losses in month 1 leads many women to quit early; the STEP-1 curve shows most loss accumulates between weeks 20 and 44, after maintenance dose is reached. If GI side effects are rough at a step, your prescriber can hold you at the current dose longer rather than escalating — a better-tolerated path than quitting.

You do not have to reach the maximum dose to benefit. Many women reach their goal at 1.7 mg semaglutide or 10 mg tirzepatide and stay there. The maintenance dose is whatever sustains your result with tolerable side effects.

Side effects: what differs for women, and how to manage them

The common side effects — nausea, constipation, diarrhea, fatigue, and the transient "sulfur burps" — occur in both sexes. In trial sub-group data women report GI side effects at modestly higher rates, likely tied to dose-per-body-weight (women receive the same fixed dose at lower average body weight). Slower titration usually resolves this.

Two side effects women ask about most: hair shedding and "Ozempic face." Both are consequences of rapid weight loss, not sex-specific drug effects. Hair shedding (telogen effluvium) affects 5-7% in trials, peaks around week 20-28, and reverses within 6-9 months once weight stabilizes — protected by adequate protein and ferritin above 70 ng/mL. Facial volume loss reflects lost facial fat; slower loss, protein, and resistance training preserve it. See our dedicated ozempic-face guide.

Gallstone risk rises with any rapid weight loss and is somewhat higher in women at baseline. Report right-upper-abdominal pain, especially after fatty meals, to your prescriber. This is a weight-loss-associated risk, not unique to GLP-1s.

What it costs, and the female-specific coverage angle

Cost is often the deciding factor between the two drugs. Brand-name list prices run near $1,000-1,600/month, but almost nobody pays that: manufacturer cash programs are $499/mo (Wegovy, NovoCare) and $349-499/mo (Zepbound, LillyDirect), and licensed compounded semaglutide via telehealth runs $99-249/mo. A covered insurance copay can be $0-25.

A coverage angle relevant to many women: PCOS-related insulin resistance can support the BMI ≥27-with-comorbidity qualifying pathway, and documented cardiovascular disease opens the SELECT-based Wegovy indication. See our full menu of cost-lowering paths for the ranked options and how to appeal a denial.

How to talk to your prescriber

Walk in with four things and the conversation goes faster. (1) Your goal — general weight loss, a specific comorbidity (PCOS, prediabetes), or cardiovascular risk reduction; the goal points to the drug. (2) Your pregnancy timeline — if you may conceive within a year, say so; it changes whether to start now. (3) Your insurance/PBM — bring the card so they can check formulary. (4) Any personal or family history of medullary thyroid cancer or MEN2, which is a contraindication.

Reasonable questions to ask: "Given my situation, do you lean semaglutide or tirzepatide, and why?" "What is my realistic loss at 6 and 12 months?" "How will we protect muscle?" "If I plateau, what is the plan?" A good prescriber welcomes these — they signal an engaged patient, which correlates with better outcomes.

When a GLP-1 is not the right choice

GLP-1s are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2, and in current pregnancy or breastfeeding. They are used cautiously with a history of pancreatitis, severe gastroparesis, or active gallbladder disease.

For women with a history of an eating disorder, appetite-suppressing medication warrants careful, specialist-involved consideration — the appetite suppression that helps most patients can be destabilizing for some. This is a genuine "not for everyone" situation, not a marketing caveat. An honest prescriber will screen for it.

Frequently asked

Is there a GLP-1 made specifically for women?

No. Wegovy, Ozempic, Zepbound, and Mounjaro all use the same mechanism and are approved for both sexes. Programs marketed "for women" are describing coaching or dosing wrappers, not a distinct drug. Trial sub-group data shows women respond similarly to or slightly better than men.

Does a GLP-1 affect birth control?

For most oral contraceptives, no clinically significant interaction is established. The exception the FDA flags is tirzepatide, which may reduce the effectiveness of oral contraceptives around dose initiation and escalation — the Zepbound label recommends adding a barrier method or switching to a non-oral contraceptive for 4 weeks after starting and after each dose increase. Confirm your specific situation with your prescriber.

Will a GLP-1 mess with my menstrual cycle?

Indirectly, and often for the better in insulin-resistant women. Weight loss and improved insulin sensitivity can regularize cycles and restore ovulation, especially in PCOS. Some women notice cycle changes as the drug takes effect. If cycles become irregular in a new or concerning way, mention it to your prescriber.

Which GLP-1 is best for PCOS?

Both semaglutide and tirzepatide improve the insulin resistance that drives PCOS and can restore ovulation. Tirzepatide produces larger mean weight loss, which may mean greater metabolic benefit, but head-to-head PCOS trials are limited. Because ovulation can return, use reliable contraception unless planning pregnancy. This is a per-patient prescriber decision.

Do women lose more weight than men on GLP-1s?

Slightly, on average, in trial sub-group analyses — but the difference is small and individual variation dominates. STEP-1 (74% female) and SURMOUNT-1 (68% female) both showed women responding similarly to or marginally better than men on the primary weight-loss endpoint.

Can I take a GLP-1 while breastfeeding?

Not recommended. The Wegovy and Ozempic labels advise against GLP-1 use during breastfeeding; the drug's transfer to human breast milk has not been fully characterized. Defer restarting until breastfeeding is complete and discuss timing with your prescriber.

Next steps

Other situations

Your situation may span more than one of these. Each guide reads the trial evidence for a different starting point.

Sources

This page describes published evidence and is not medical advice. GLP-1 drug selection is a decision for a licensed prescriber who has assessed you individually.

Best GLP-1 for Women 2026 — Evidence Review (STEP + SURMOUNT)